Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 240,000 Shares of Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 240,000 shares of Nuvectis Pharma stock in a transaction that occurred on Friday, February 7th. The shares were bought at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the transaction, the insider now owns 2,884,121 shares in the company, valued at $14,420,605. This represents a 9.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri bought 17,000 shares of Nuvectis Pharma stock. The stock was bought at an average cost of $4.70 per share, with a total value of $79,900.00.

Nuvectis Pharma Trading Down 0.6 %

Shares of Nuvectis Pharma stock traded down $0.04 during midday trading on Tuesday, reaching $6.29. The company had a trading volume of 54,546 shares, compared to its average volume of 119,724. The stock has a fifty day simple moving average of $5.63 and a 200 day simple moving average of $6.34. Nuvectis Pharma, Inc. has a 1-year low of $4.44 and a 1-year high of $12.10. The company has a market capitalization of $121.52 million, a price-to-earnings ratio of -5.42 and a beta of 0.22.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NVCT. Oppenheimer & Co. Inc. acquired a new position in shares of Nuvectis Pharma during the fourth quarter valued at $135,000. Nations Financial Group Inc. IA ADV increased its position in Nuvectis Pharma by 35.0% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock worth $73,000 after purchasing an additional 3,500 shares during the period. Forbes J M & Co. LLP raised its holdings in Nuvectis Pharma by 21.9% during the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock worth $319,000 after purchasing an additional 10,599 shares during the last quarter. Baldwin Wealth Partners LLC MA lifted its position in Nuvectis Pharma by 104.4% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock valued at $1,926,000 after purchasing an additional 181,831 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Nuvectis Pharma by 49.8% in the 3rd quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock valued at $501,000 after purchasing an additional 26,489 shares during the last quarter. 96.77% of the stock is currently owned by institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.